nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.06.2013 | Research Paper

FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma

verfasst von: Michael L. Megison, Jerry E. Stewart, Hugh C. Nabers, Lauren A. Gillory, Elizabeth A. Beierle

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Neuroblastoma, the most common extracranial solid tumor of childhood, is responsible for over 15 % of pediatric cancer deaths. We have shown that neuroblastoma cell lines overexpress focal adhesion kinase (FAK), a non-receptor protein tyrosine kinase that controls a number of tumorigenic pathways. In this study, we hypothesized that inhibition of FAK would result in decreased cellular migration and invasion in neuroblastoma cell lines, and decrease metastasis in a murine model. We utilized non-isogenic and isogenic MYCN human neuroblastoma cell lines and parallel methods of FAK inhibition. Cell viability, migration, and invasion assays were employed to assess the effects of FAK inhibition in vitro. A nude mouse model was utilized to determine the effects of FAK inhibition on in vivo liver metastasis. FAK knockdown with siRNA resulted in decreased invasion and migration in neuroblastoma cell lines, and the effects of siRNA-induced FAK inhibition were more pronounced in MYCN amplified cell lines. In addition, abrogation of FAK with a small molecule inhibitors resulted in decreased cell survival, migration and invasion in neuroblastoma cell lines, again most pronounced in cell lines with MYCN amplification. Finally, small molecule FAK inhibition in a nude mouse model resulted in a significant decrease in metastatic tumor burden in SK-N-BE(2) injected animals. We believe that FAK plays an important role in maintaining and propagating the metastatic phenotype of neuroblastoma cells, and this driver role is exaggerated in cell lines that overexpress MYCN. FAK inhibition warrants further investigation as a potential therapeutic target in the treatment of aggressive neuroblastoma.

Nur mit Berechtigung zugänglich

Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. J Clin Oncol 17:2263–2279

Cotterill SJ, Parker L, More L, Craft AW (2001) Neuroblastoma: changing incidence and survival in young people aged 0–24 years. A report from the North of England young person’s malignant disease registry. Med Pediatr Oncol 36:231–234PubMedCrossRef

Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced stage disease. Science 224:1121–1124PubMedCrossRef

Seeger RC, Brodeur GM, Sather H, Dalton A, Siegle SE, Wong KY, Hammond D (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111–1116PubMedCrossRef

Zaizen Y, Taniguchi S, Noguchi S, Suita S (1993) The effect of N-myc amplification and expression on invasiveness of neuroblastoma cells. J Pediatr Surg 28:766–769PubMedCrossRef

Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH (2006) MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun 351:192–197PubMedCrossRef

Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, Fukuzawa M (2007) Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol 30:1189–1196PubMed

Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT (1992) pp 125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 89:5192–5196PubMedCrossRef

Hanks SK, Polte TR (1997) Signaling through focal adhesion kinase. BioEssays 19:137–145PubMedCrossRef

10.

Zachary I (1997) Focal adhesion kinase. Int J Biochem Cell Biol 29:929–934PubMedCrossRef

11.

Gabarra-Niecko V, Schaller MD, Dunty JM (2003) FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 22:359–374PubMedCrossRef

12.

Xu LH, Yang XH, Bradham CA, Brenner DA, Baldwin AS, Craven RJ, Cance WG (2000) The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J Biol Chem 275:30597–30604PubMedCrossRef

13.

Xu LH, Yang XH, Craven RJ, Cance WG (1998) The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ 9:999–1005PubMed

14.

Xu LH, Owens LV, Sturge GC, Yang X, Liu ET, Craven RJ, Cance WG (1996) Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ 7:413–418PubMed

15.

Golubovskaya VM, Beviglia L, Xu LH, Earp HS, Craven RJ, Cance W (2002) Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 277:38978–38987PubMedCrossRef

16.

Han EK, Mcgonigal T, Wang J, Giranda VL, Luo Y (2004) Functional analysis of focal adhesion kinase (FAK) reduction by small inhibitory RNAs. Anticancer Res 24:3899–3905PubMed

17.

Lipinski CA, Tran NL, Menashi E, Rohl C, Kloss J, Bay RC, Berens ME, Loftus JC (2005) The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia 7:435–445PubMedCrossRef

18.

Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282:14845–14852PubMedCrossRef

19.

Wendt MK, Schiemann WP (2009) Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res 11:R68PubMedCrossRef

20.

Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG (2008) A small molecule inhibitor, 1, 2, 4, 5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 51:7405–7416PubMedCrossRef

21.

Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG, Golubovskaya VM (2010) Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle 9:1005–1015PubMedCrossRef

22.

Golubovskaya VM, Virnig C, Cance WG (2008) TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 47:222–234PubMedCrossRef

23.

Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, deGroot J, Yung WK (2007) Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 6:1357–1367PubMedCrossRef

24.

Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK (2007) Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67:10976–10983PubMedCrossRef

25.

Beierle EA, Massoll NA, Hartwich J, Kurenova EV, Golubovskaya VM, Cance WG, McGrady P, London WB (2008) Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin Cancer Res 14:3299–3305PubMedCrossRef

26.

Beierle EA, Trujillo A, Nagaram A, Kurenova EV, Finch R, Ma X, Vella J, Cance WG, Golubovskaya VM (2007) N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem 282:12503–12516PubMedCrossRef

27.

Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M (1990) Augmented MYCN expression enhances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 50:411–416

28.

Hao HF, Takaoka M, Bao XH, Wang ZG, Tomono Y, Sakurama K, Ohara T, Fukazawa T, Yamatsuji T, Fujiwara T, Naomoto Y (2012) Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer. Biochem Biophys Research Commun 423:744–749CrossRef

29.

Sakurama K, Noma K, Takaoka M, Tomono Y, Watanabe N, Hatakeyama S, Ohmori O, Hirota S, Motoki T, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Tanaka N, Naomoto Y (2009) Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Mol Cancer Ther 8:127–134PubMedCrossRef

30.

Ucar K, Seeger RC, Challita PM, Watanabe CT, Yen TL, Morgan JP, Amado R, Chou E, McCallister T, Barber JR, Jolly DJ, Reynolds CP, Gangavalli R, Rosenblatt JD (1995) Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector. Cancer Gene Ther 2:171–181PubMed

31.

Nguyen T, Hocker JE, Thomas W, Smith SA, Norris MD, Haber M, Cheung B, Marshall GM (2003) Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells. Biochem Biophys Res Comm 302:462–468PubMedCrossRef

32.

Bandapalli OR, Paul E, Schirmacher P, Brand K (2012) Opposite effects of tissue inhibitor of metalloproteinases-1 (TIMP-1) over-expression and knockdown on colorectal liver metastases. BMC Res Notes 5:14PubMedCrossRef

33.

Hawcroft G, Volpato M, Marston G, Ingram N, Perry SL, Cockbain AJ, Race AD, Munarini A, Belluzzi A, Loadman PM, Coletta PL, Hull MA (2012) The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of prostaglandin E(2)-dependent cell motility. Br J Pharmacol 166:1724–1737PubMedCrossRef

34.

Goodman LA, Liu BC, Thiele CJ, Schmidt ML, Cohn SL, Yamashiro JM, Pai DS, Ikegaki N, Wada RK (1997) Modulation of N-myc expression alters the invasiveness of neuroblastoma. Clin Exp Metastasis 15:130–139PubMedCrossRef

35.

Weinstein IB (2002) Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science 297:63–64PubMedCrossRef

36.

Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077–3080PubMedCrossRef

37.

Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619–626PubMedCrossRef

38.

Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY (1996) Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134:793–799PubMedCrossRef

39.

Ocak S, Yamashita H, Udyavar AR, Miller AN, Gonzalez AL, Zou Y, Jiang A, Yi Y, Shyr Y, Estrada L, Quaranta V, Massion PP (2010) DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene 29:6331–6342PubMedCrossRef

40.

Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, Tonghua L (2009) Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 8:125PubMedCrossRef

41.

Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, Coleman K, Yao L, Martinez-Alsina L, Lorenzen M, Berliner M, Luzzio M, Patel N, Schmitt E, LaGreca S, Jani J, Wessel M, Marr E, Griffor M, Vajdos F (2008) Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562, 271. Cancer Res 68:1935–1944PubMedCrossRef

42.

Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN (2007) A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 46:488–496PubMedCrossRef

43.

Beierle EA, Trujillo A, Nagaram A, Golubovskaya VM, Cance WG, Kurenova EV (2008) TAE226 inhibits human neuroblastoma cell survival. Cancer Invest 26:145–151PubMedCrossRef

Titel: FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma
verfasst von: Michael L. Megison
Jerry E. Stewart
Hugh C. Nabers
Lauren A. Gillory
Elizabeth A. Beierle
Publikationsdatum: 01.06.2013
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 5/2013
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-012-9560-7

Springer Medizin

FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Leading malignant cells initiate collective epithelial cell invasion in a three-dimensional heterotypic tumor spheroid model

Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma

Increased growth of colorectal liver metastasis following partial hepatectomy

Integrin alpha2beta1 (α2β1) promotes prostate cancer skeletal metastasis

Hypofractionated radiotherapy with Tomotherapy for patients with hepatic oligometastases: retrospective analysis of two institutions

Kurt Hellmann D. M., D. Phil. Oxon 1922–2013

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie